Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orhan Sezer

Showing results (51-60 of 109) with videos related to

Pageof 11
Sort By:
Journal of Cancer Research and Clinical Oncology|July 10, 2003
Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletionIvana Zavrski, Cord Naujokat, Kathrin Niemöller, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 17, 2008
mTOR regulates vascular smooth muscle cell differentiation from human bone marrow-derived mesenchymal progenitorsBjörn Hegner, Maria Lange, Angelika Kusch, et al.
Journal of Cancer Research and Clinical Oncology|July 27, 2005
Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II studyPeter Schmid, Volker Heilmann, Carsten-Oliver Schulz, et al.
Anti-Cancer Drugs|October 30, 2004
Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myelomaJan Eucker, Katharina Bängeroth, Ivana Zavrski, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 16, 2011
Information disclosure to cancer patients: EORTC QLQ-INFO25 questionnaireJuan Ignacio Arraras, Eva Greimel, Wei-Chu Chie, et al.
Anti-Cancer Drugs|October 24, 2002
The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomasJan Eucker, Claudia Schille, Peter Schmid, et al.
Psycho-Oncology|November 5, 2011
Cross-cultural differences in information disclosure evaluated through the EORTC questionnairesJuan Ignacio Arraras, Eva Greimel, Wei-Chu Chie, et al.
Clinical Lymphoma & Myeloma|January 19, 2007
Bortezomib-induced tumor lysis syndrome in multiple myelomaOrhan Sezer, David H Vesole, Seema Singhal, et al.
European Journal of Cancer (Oxford, England : 1990)|August 3, 2010
An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patientsJuan Ignacio Arraras, Eva Greimel, Orhan Sezer, et al.
Journal of Cancer Research and Clinical Oncology|June 19, 2004
Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cellsUlrike Heider, Ivana Zavrski, Christian Jakob, et al.
Pageof 11

Showing results (51-60 of 109) with videos related to

Sort By:
Pageof 11
Journal of Cancer Research and Clinical Oncology|July 10, 2003
Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletionIvana Zavrski, Cord Naujokat, Kathrin Niemöller, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 17, 2008
mTOR regulates vascular smooth muscle cell differentiation from human bone marrow-derived mesenchymal progenitorsBjörn Hegner, Maria Lange, Angelika Kusch, et al.
Journal of Cancer Research and Clinical Oncology|July 27, 2005
Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II studyPeter Schmid, Volker Heilmann, Carsten-Oliver Schulz, et al.
Anti-Cancer Drugs|October 30, 2004
Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myelomaJan Eucker, Katharina Bängeroth, Ivana Zavrski, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 16, 2011
Information disclosure to cancer patients: EORTC QLQ-INFO25 questionnaireJuan Ignacio Arraras, Eva Greimel, Wei-Chu Chie, et al.
Anti-Cancer Drugs|October 24, 2002
The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomasJan Eucker, Claudia Schille, Peter Schmid, et al.
Psycho-Oncology|November 5, 2011
Cross-cultural differences in information disclosure evaluated through the EORTC questionnairesJuan Ignacio Arraras, Eva Greimel, Wei-Chu Chie, et al.
Clinical Lymphoma & Myeloma|January 19, 2007
Bortezomib-induced tumor lysis syndrome in multiple myelomaOrhan Sezer, David H Vesole, Seema Singhal, et al.
European Journal of Cancer (Oxford, England : 1990)|August 3, 2010
An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patientsJuan Ignacio Arraras, Eva Greimel, Orhan Sezer, et al.
Journal of Cancer Research and Clinical Oncology|June 19, 2004
Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cellsUlrike Heider, Ivana Zavrski, Christian Jakob, et al.
Pageof 11